ZBH — ZIMMER BIOMET HOLDINGS
Institutional ESEN Master Score | Health Care Medical Devices | NYSE
| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 64 | Mixed growth/valuation backdrop; forward PE 10.82 attractive but EPS declining YoY; beta 0.46 defensive; dividend 1.04% yield provides cushion | 6–12M |
| SA Quality/Value Composite | B− | 72 | PE 27.07 elevated vs. sector median; forward PE 10.82 significantly discounted; PEG ratio negative (−1.85) due to −14.64% EPS contraction YoY; revenue growth +9.23% provides some offset | Trailing |
| Zacks Earnings Momentum | D | 42 | EPS down −14.64% YoY; no earnings date disclosed; forward PE 10.82 implies modest terminal growth recovery assumption; weak near-term earnings surprise probability | 3–6M |
| Institutional & Smart Money Flow | C | 58 | Beta 0.46 suggests defensive positioning; trading below 52-week high (−12.3%); dividend yield 1.04% attractive to income-focused allocators; limited visibility on recent insider activity | 1–3M |
| Growth Sustainability & Moat | C+ | 62 | Revenue growth +9.23% YoY moderate but stable; health-care sector structural tailwinds; EPS contraction signals margin pressure or one-time charges; PE compression suggests market skepticism on durability | 6–12M |
| Valuation & Safety (Pre-Penalty) | B | 78 | Forward PE 10.82 well below historical mean (~15–17); current PE 27.07 reflects one-time headwind; price −2.23% intraday; 52-week return +1.76% neutral; downside risk limited by beta 0.46 | 3–12M |
| Penalty Overlay | −8 pts | −8 | EPS momentum deterioration (−14.64% YoY) warrants 8-point deduction; offset partially by low beta defensive profile and forward valuation discount; no data gaps on critical fundamentals | Trailing |
| CONFIDENCE SCORE | B− | 76 | Complete quote, metrics, and profile data; earnings date and revenue TTM not disclosed but forward PE and revenue growth YoY sufficient for thesis; no material data gaps impacting conclusion | Trailing |
| Volatility & Drawdown Risk | A− | 88 | Beta 0.46 low volatility; current price $94.98 trading −12.3% below 52-week high; intraday swing −2.23%; limited downside to 52-week low $79.12 (−16.8% further); cushion from dividend yield | 1–3M |
| Crowding Risk Flag | C | 55 | Low beta and dividend yield may attract passive/income flows; market-cap $19.1B mid-cap liquid; avg volume 2.19M shares; no hyper-growth flag (negative PEG) reduces crowding from momentum traders; defensive positioning popular post-correction | 3–6M |
Zimmer Biomet operates in the fragmented orthopedic and surgical devices sector, competing against peers including Stryker (SYK), Johnson & Johnson (JNJ), and Medtronic (MDT). ZBH's current valuation—PE 27.07 trailing, forward PE 10.82—reflects a compressed multiple consistent with a cyclical trough in device utilization or product mix headwinds post-pandemic normalization. Revenue growth of +9.23% YoY places ZBH in the middle quintile for large-cap medtech, while the −14.64% EPS decline signals either margin compression, restructuring charges, or a one-time litigation/warranty reserve adjustment. The low beta (0.46) is consistent with healthcare defensiveness, though institutional accumulation patterns remain opaque. Comparable peers trade at forward PE 12–14, suggesting ZBH's 10.82 forward multiple offers 15–25% relative upside if earnings stabilize.
1–3 Month Outlook
Consolidation Likely. With intraday volatility (−2.23%) and EPS momentum headwinds, expect trading in $90–$98 range. Lack of disclosed earnings guidance limits upside catalyst; however, dividend yield (1.04%) and low beta (0.46) attract defensive rotation. Watch for Q3 earnings beat as sentiment inflection point. Risk: further margin misses extend EPS downtrend.
6–12 Month Outlook
Recovery Probable. Revenue growth (+9.23%) should drive margin expansion and EPS recovery off the trough. Forward PE 10.82 offers 20–30% upside if EPS stabilizes to $4.00+. Sector tailwinds (aging population, elective procedure normalization) support medium-term thesis. Key risk: if revenue growth decelerates below 5% YoY, re-rating to 8–9x forward PE is possible.
Data As Of: 2026-07-31 13:54:02 UTC | Source: Finnhub (quote, metrics, profile) | Methodology: ESEN Master V3.5-LIVE | Disclaimers: This analysis is for informational purposes. Equity valuations are subject to rapid change. Forward projections reflect available disclosed data only; no earnings guidance date disclosed. Past performance does not guarantee future results.
ZBH Systematic Research
Zimmer Biomet Holdings presents a distinctive risk-return profile in the orthopedic device sector, with systematic screening highlighting a beta of 0.46 that positions the equity as notably defensive relative to broader market volatility. Trading at $93.93 within a 52-week range of $79.12 to $108.29, the stock currently reflects 13.3% downside from its recent peak, a technical pattern warranting quantitative review given the company's fundamental metrics.
The revenue growth trajectory of 9.23% year-over-year contrasts sharply with EPS contraction of -14.64%, a divergence that systematic models flag as margin compression or increased operating costs. Net margin of 9.05% supports continued profitability, yet the ROE of 6.01% and ROI of 3.74% fall below medical device industry norms, suggesting capital efficiency challenges. The company maintains a gross margin of 70.03%, demonstrating pricing power in specialized orthopedic implants and surgical technologies, while the operating margin of 14.02% indicates substantial overhead absorption.
Fundamental screening identifies several positioning factors:
- Balance sheet stability with a debt-to-equity ratio of 0.59 and current ratio of 1.98, providing operational flexibility
- Valuation at 24.52x trailing earnings and 2.22x sales appears moderate for the healthcare equipment sector
- Price-to-book of 1.4 relative to $64.95 book value per share suggests reasonable asset-based valuation
- Low beta characteristics appeal to volatility-sensitive portfolio construction models
Compared to peers BDX, IDXX, and DXCM, Zimmer operates in the mature joint reconstruction segment with inherently lower growth expectations but established market positions. The EPS contraction amid revenue expansion remains the primary quantitative concern in multi-factor screening frameworks.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.